Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain block could cut opioid use after mastectomy

NCT ID NCT07562945

Symptom relief Sponsor: Aldy Aldy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a continuous nerve block using the numbing drug ropivacaine can reduce pain, inflammation, and opioid use in women undergoing mastectomy for breast cancer. Forty women will be randomly assigned to receive the nerve block or standard pain care. Researchers will measure pain scores, opioid consumption, and markers of inflammation in the first 24 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ropivacaine
What this could lead to
If it works, this could offer a better way to manage pain after mastectomy, reducing the need for opioids and possibly improving recovery.
What could go wrong
This is a small, early-stage trial with only 40 participants, so results may not apply to everyone. The nerve block carries rare risks like infection or allergic reaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18 to 65 years * Diagnosed with breast cancer * Scheduled for elective mastectomy under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-III * Able to understand and provide written informed consent * Body mass index (BMI) 18-29 kg/m² Exclusion Criteria: * Contraindications to regional anesthesia * Contraindications or allergy to ropivacaine or local anesthetics * Inability to use a visual analog scale (VAS) for pain assessment * Inability to understand or operate patient-controlled analgesia (PCA) * History of chronic pain or ongoing infection requiring treatment * History of chronic analgesic use * History of autoimmune disease * Uncontrolled systemic disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Postoperative pain, acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ngoerah Hospital

    Denpasar, Bali, 80113, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.